The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive Breast Cancer
BACKGROUND AND OBJECTIVE: The effectiveness of ovarian function suppression therapies in patients with non-menopausal breast cancer has not yet been established. This study was performed to evaluate the role of gonadotropin-releasing hormone agonist (GnRH agonist) receptor in reducing local recurren...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Babol University of Medical Sciences
2020-03-01
|
| Series: | Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul |
| Subjects: | |
| Online Access: | http://jbums.org/article-1-9484-en.html |
| _version_ | 1819002132631650304 |
|---|---|
| author | S Akbarzadeh Pasha A Gholizadeh Pasha M Raanaee A Moghadamnia A Vallard D Moslemi |
| author_facet | S Akbarzadeh Pasha A Gholizadeh Pasha M Raanaee A Moghadamnia A Vallard D Moslemi |
| author_sort | S Akbarzadeh Pasha |
| collection | DOAJ |
| description | BACKGROUND AND OBJECTIVE: The effectiveness of ovarian function suppression therapies in patients with non-menopausal breast cancer has not yet been established. This study was performed to evaluate the role of gonadotropin-releasing hormone agonist (GnRH agonist) receptor in reducing local recurrence or metastasis in non-menopausal women with localized breast cancer.
METHODS: This clinical trial was performed on 104 non-menopausal women with localized and advanced localized breast cancer (in stages 2 and 3) with positive hormone receptor (HR+) in the two groups of control and intervention with GnRH analog. The control group received standard treatment at the time of the study, which included tamoxifen. The GnRHa group received 3.75 mg triptorelin subcutaneously per month in addition to the standard treatment. Patients were evaluated for local recurrence and metastasis within 36 months.
FINDINGS: The mean age of patients was 39.78±3.99 years. 9 patients in the control group (mean metastasis time of 17±6.65 months) and 6 patients in the GnRHa group (mean metastasis time of 14.33±8.12 months) had metastasis (p=0.498). The 36-month disease-free survival was 83.3% in the control group and 88% in the GnRHa group (p=0.518). 36-month disease-free survival in patients with HER2, 1+ or higher levels was greater in the GnRHa group compared to controls (p=0.049). In patients who received GnRH analogues, patients with HER2/neu 1+ and above had 20.7% less metastasis than patients with HER2 0 (p=0.029). However, this significant difference was not seen in the control group and other variables.
CONCLUSION: According to the results of this study, GnRH analogues do not have a significant effect on reducing the rate of metastasis in patients who received it compared to other patients in a short-term period. |
| first_indexed | 2024-12-20T23:00:15Z |
| format | Article |
| id | doaj.art-9b9ce32c676f44879abf4106d476d79b |
| institution | Directory Open Access Journal |
| issn | 1561-4107 2251-7170 |
| language | English |
| last_indexed | 2024-12-20T23:00:15Z |
| publishDate | 2020-03-01 |
| publisher | Babol University of Medical Sciences |
| record_format | Article |
| series | Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul |
| spelling | doaj.art-9b9ce32c676f44879abf4106d476d79b2022-12-21T19:24:01ZengBabol University of Medical SciencesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul1561-41072251-71702020-03-01221290297The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive Breast CancerS Akbarzadeh Pasha0A Gholizadeh Pasha1M Raanaee2A Moghadamnia3A Vallard4D Moslemi5 1. School of Medicine, Babol University of Medical Sciences, Babol, I.R.Iran 2. Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran 2. Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran 2. Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran 3. Department of Radiation Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest en Jarez, France 4. Department of Radiation Oncology, School of Medicine, Babol University of Medical Sciences, Babol, I.R.Iran BACKGROUND AND OBJECTIVE: The effectiveness of ovarian function suppression therapies in patients with non-menopausal breast cancer has not yet been established. This study was performed to evaluate the role of gonadotropin-releasing hormone agonist (GnRH agonist) receptor in reducing local recurrence or metastasis in non-menopausal women with localized breast cancer. METHODS: This clinical trial was performed on 104 non-menopausal women with localized and advanced localized breast cancer (in stages 2 and 3) with positive hormone receptor (HR+) in the two groups of control and intervention with GnRH analog. The control group received standard treatment at the time of the study, which included tamoxifen. The GnRHa group received 3.75 mg triptorelin subcutaneously per month in addition to the standard treatment. Patients were evaluated for local recurrence and metastasis within 36 months. FINDINGS: The mean age of patients was 39.78±3.99 years. 9 patients in the control group (mean metastasis time of 17±6.65 months) and 6 patients in the GnRHa group (mean metastasis time of 14.33±8.12 months) had metastasis (p=0.498). The 36-month disease-free survival was 83.3% in the control group and 88% in the GnRHa group (p=0.518). 36-month disease-free survival in patients with HER2, 1+ or higher levels was greater in the GnRHa group compared to controls (p=0.049). In patients who received GnRH analogues, patients with HER2/neu 1+ and above had 20.7% less metastasis than patients with HER2 0 (p=0.029). However, this significant difference was not seen in the control group and other variables. CONCLUSION: According to the results of this study, GnRH analogues do not have a significant effect on reducing the rate of metastasis in patients who received it compared to other patients in a short-term period.http://jbums.org/article-1-9484-en.htmlbreast neoplasmtriptorelingonadotropin-releasing hormone (gnrh)erbb-2 receptor. |
| spellingShingle | S Akbarzadeh Pasha A Gholizadeh Pasha M Raanaee A Moghadamnia A Vallard D Moslemi The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive Breast Cancer Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul breast neoplasm triptorelin gonadotropin-releasing hormone (gnrh) erbb-2 receptor. |
| title | The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive
Breast Cancer |
| title_full | The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive
Breast Cancer |
| title_fullStr | The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive
Breast Cancer |
| title_full_unstemmed | The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive
Breast Cancer |
| title_short | The Role of Gnrh Analogues in 36-Month Disease-Free Survival in Non-Menopausal Patients with Hormone Receptor-Positive
Breast Cancer |
| title_sort | role of gnrh analogues in 36 month disease free survival in non menopausal patients with hormone receptor positive breast cancer |
| topic | breast neoplasm triptorelin gonadotropin-releasing hormone (gnrh) erbb-2 receptor. |
| url | http://jbums.org/article-1-9484-en.html |
| work_keys_str_mv | AT sakbarzadehpasha theroleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT agholizadehpasha theroleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT mraanaee theroleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT amoghadamnia theroleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT avallard theroleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT dmoslemi theroleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT sakbarzadehpasha roleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT agholizadehpasha roleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT mraanaee roleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT amoghadamnia roleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT avallard roleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer AT dmoslemi roleofgnrhanaloguesin36monthdiseasefreesurvivalinnonmenopausalpatientswithhormonereceptorpositivebreastcancer |